Hide metadata

dc.date.accessioned2023-11-15T16:49:18Z
dc.date.available2023-11-15T16:49:18Z
dc.date.created2023-08-30T12:46:32Z
dc.date.issued2023
dc.identifier.citationPawel, Mielnik Sexton, Joseph Fagerli, Karen Minde Bakland, Gunnstein Hu, Yi Kristianslund, Eirik Hoff, Mari Wierød, Ada Kvien, Tore Kristian Aaserud . Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD). Rheumatology - Advances in Practice (Rheumap). 2023, 7(2)
dc.identifier.urihttp://hdl.handle.net/10852/105872
dc.description.abstractAbstract Objectives MTX, LEF and SSZ are conventional synthetic DMARDs (csDMARDs) with a well-established role in the treatment of RA. We aimed to estimate and compare the relative risks for adverse events (AEs) and the discontinuation of these drugs owing to AEs. Methods We included all 3339 patients from the NOR-DMARD study treated with MTX, LEF or SSZ in monotherapy. All reported AEs were compared between treatment groups using quasi-Poisson regression. In addition, drug retention rates were analysed using Kaplan–Meier estimates with Cox regression to control for possible confounders. We analysed drug retention rates and cumulative risk of discontinuation attributable to AEs using the Kaplan–Meier estimator. We assessed age, sex, baseline DAS in 28 joints with ESR (DAS28-ESR), seropositivity, prednisolone use, previous DMARD use, year of inclusion and co-morbidity as possible cofounders. Results We found that the discontinuation rate attributable to AEs was significantly higher for LEF and SSZ than for MTX. After the first year, it was 13.7% (95% CI 12.2, 15.2), 39.6% (95% CI 34.8, 44) and 43.4% (95% CI 38.2, 48.1) for MTX, SSZ and LEF, respectively. Similar results were found when adjusting for confounders. The overall AEs were comparable across the treatment groups. The AE profile was as expected for each drug. Conclusion Our work has shown a similar AE profile of csDMARDs to previous data. However, higher discontinuation rates for SSZ and LEF cannot be explained easily from AE profiles.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleDiscontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)
dc.title.alternativeENEngelskEnglishDiscontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)
dc.typeJournal article
dc.creator.authorPawel, Mielnik
dc.creator.authorSexton, Joseph
dc.creator.authorFagerli, Karen Minde
dc.creator.authorBakland, Gunnstein
dc.creator.authorHu, Yi
dc.creator.authorKristianslund, Eirik
dc.creator.authorHoff, Mari
dc.creator.authorWierød, Ada
dc.creator.authorKvien, Tore Kristian Aaserud
cristin.unitcode185,50,0,0
cristin.unitnameDet medisinske fakultet
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2170911
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Rheumatology - Advances in Practice (Rheumap)&rft.volume=7&rft.spage=&rft.date=2023
dc.identifier.jtitleRheumatology - Advances in Practice (Rheumap)
dc.identifier.volume7
dc.identifier.issue2
dc.identifier.pagecount0
dc.identifier.doihttps://doi.org/10.1093/rap/rkad053
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2514-1775
dc.type.versionPublishedVersion
cristin.articleidrkad053
dc.relation.projectNFR/328657


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International